Transthyretin amyloidosis cardiomyopathy (ATTR-CM) is an increasingly recognized and potentially life-limiting cause of heart failure, characterized by the deposition of misfolded transthyretin protein in the myocardium, leading to progressive cardiac dysfunction and a range of cardiovascular complications. Recent years have witnessed transformative advances in both the diagnosis and management of ATTR-CM, with the emergence of novel therapeutic agents—including transthyretin stabilizers, gene silencers, and experimental amyloid fibril depleters—offering new hope for patients who previously faced limited treatment options and poor prognoses. This professional education program, ‘Therapeutic Advances in Transthyretin Amyloidosis Cardiomyopathy,’ led by international expert faculty Drs. Ahmad Masri and Mazen Hanna and focusing on new data released at the 2025 American College of Cardiology meeting, is designed to equip clinicians with the latest knowledge on evolving diagnostic strategies, the expanding therapeutic landscape, and the practical integration of these innovations into patient care, ultimately aiming to improve outcomes and quality of life for individuals affected by this challenging disease.
Cardiologists, advanced practice providers, nurses, and other health care professionals involved in the treatment of patients with ATTR-CM
Review the genetics and pathogenesis of ATTR-CM, as well as existing treatment guidelines (US and European) and how those factors inform approaches to patient identification and recognition of heart failure risk
Analyze clinical trial data presented at ACC2025 for the treatment of patients with ATTR-CM
Evaluate practical strategies to incorporate new data into current and future practice in the management of individuals with ATTR-CM
ACC 2025 Conference Review and Analysis
a. Clinical Trial Data Review and Practical Applications for New and Emerging Therapeutics to Manage Patients with ATTR-CM
b. Long Term Treatment Strategies to Optimize Outcomes in Patients with ATTR-CM
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships with ineligible companies. Planners have no relevant financial relationships with ineligible companies to disclose related to this activity. Faculty
have disclosed the following relevant financial relationships. All relevant financial relationships have been mitigated.
| Faculty | Relationship Identified With: |
| Mazen Hanna, MD | Consultant/Advisor: Akros Pharma Inc.; Alexion Pharmaceuticals, Inc; Alnylam Pharmaceuticals; AstraZeneca; Attralus, Inc.; Avidity Biosciences; Cytokinetics; BioMarin; BridgeBio Pharma, Inc.; Bristol-Myers Squibb Company; Edgewise Therapeutics; Haya Therapeutics; Ionis Pharmaceuticals; Lexicon Pharmaceuticals, Inc.; Lexeo Therapeutics, Inc.; Neurimmune; Pfizer Inc.; Prothena; Rocket Pharmaceuticals, Ltd; Tenaya Therapeutics Grant/Research Support: Attralus, Inc.; Cytokinetics; Ionis Pharmaceuticals; Johnson & Johnson Services, Inc.; Pfizer Inc. |
| Ahmad Masri, MD, MS | Consultant/Advisor: Alexion Pharmaceuticals, Inc; Alnylam Pharmaceuticals; Attralus, Inc.; BridgeBio Pharma, Inc.; Pfizer Inc.; Novo Nordisk A/S |
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Simonds hereby state that they do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 CreditTM.
Participants should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Alnylam Pharmaceuticals.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Alnylam Pharmaceuticals do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
In order to claim credit, participants must complete the following:
For all CE inquiries or special needs, please contact admin@academiccme.com.
811 S. Orleans Ave. Tampa, Fl 33606
